A phase 2 study assessed CHOP plus rituximab (R‐CHOP) in HIV‐associated B‐cell NHL, revealing a CR rate of 77% and a 2 year‐survival rate of 75%, which suggests that rituximab is beneficial and safe.8 Here, DDIT3 is linked to B-cell non-Hodgkin lymphoma.